McGurk KA, Bilgehan N, Ware JS. Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy. Circulation. 2024;149(23):1786-1788. doi:10.1161/CIRCULATIONAHA.123.066916.

McGurk KA, Bilgehan N, Ware JS. Pharmacogenetic Influences Over Mavacamten Pharmacokinetics: Considerations for the Treatment of Individuals With Hypertrophic Cardiomyopathy. Circulation. 2024;149(23):1786-1788. doi:10.1161/CIRCULATIONAHA.123.066916.

Cirino AL, Lakdawala NK, McDonough B, et al. A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017;10(5). doi:10.1161/CIRCGENETICS.117.001768.

Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet. 2012;91(3):513-9. doi:10.1016/j.ajhg.2012.07.017.

Keshishian H, Burgess MW, Gillette MA, et al. Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury. Mol Cell Proteomics. 2015;14(9):2375-93. doi:10.1074/mcp.M114.046813.

Ngo D, Sinha S, Shen D, et al. Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation. 2016;134(4):270-85. doi:10.1161/CIRCULATIONAHA.116.021803.